Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

(

ACCESS

)

ITN Protocol #:

ITN034AI

Branded Name:

ACCESS

ClinicalTrials.Gov ID:

NCT00774852

Treatment Protocol #:

Abatacept

Therapeutic Area:

Autoimmune Disease

Current Status:

Complete

ITN Website Clinical Trial Recruiting Site Document Portal Location Study on ITN TrialShare

Summary:

A Randomized, Double-blind, Controlled, Phase II Multicenter Trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs Cyclophosphamide Alone in the Treatment of Lupus Nephritis

Clinical Operations Manager

ITN Biologist

NIAID Project Manager

Rho Data Manager

Study Personnel:

Protocol Chair

Betty Diamond, MD bdiamond@nshs.edu

Work:

516-562-3830

Protocol Chair

David Wofsy, MD wofsyd@medsch.ucsf.edu

Work:

415-750-2104

Protocol Chair

Patti Tosta ptosta@immunetolerance.org

Work:

415-353-4421

Protocol Chair

Kristina Harris, PhD

Work:

Protocol Chair

Wendy Gao gaowe@mail.nih.gov

Work:

240-627-3471

Protocol Chair

LaSonia Morgan LaSonia_Morgan@rhoworld.com

Work:

919-595-6379

Admin Links

Shortcuts

ITN Documents

Links